Hearing Loss Clinical Trials

Find Hearing Loss Clinical Trials Near You

BREEDBAND TYMPANOMETRIE ALS EEN NIET-GEDRAGSMATIGE TEST VAN DE SPRAAK-GEWOGEN MIDDENOOR TRANSFER FUNCTIE.

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

There is a need for a non-behavioral clinical test that provides an assessment of how speech is conducted through the middle ear for the optimization of middle ear implants. These implants utilize the functionality of the human middle ear and require adequate speech conduction through the middle ear chain. Consequently, the clinical test of this degree of speech transfer can contribute to the pre-operative indication for middle ear implants. Wideband Tympanometry (WT) is a non-invasive diagnostic tool for the clinical assessment of the condition of the middle ear. Unlike classical tympanometry, WT tests the impedance of the middle ear system as a function of both pressure and frequencies. Consequently, a WT measurement contains many times more information about the functionality of the middle ear than classical tympanometry and is ideally suited as a diagnostic tool for the clinical assessment of speech transfer through the middle ear. The WT measurements will be correlated with the Speech Intelligibility Index (SII) collected in normally hearing individuals and patients with isolated conductive hearing loss. This index is a measure of speech transfer through the middle ear. Consequently, a correlation of the WT measurements with the SII addresses the need for a non-behavioral clinical test of speech transfer through the middle ear. Additionally, WT measurements will be performed longitudinally in cochlear implant candidates, one of the populations that can benefit from the developed clinical test. These longitudinal WT measurements, which will be performed both pre- and post-operatively, allow for the evaluation of the impact of middle ear surgery on the predicted SII.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• NH subjects

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.

• At least 18 years of age at the time of signing the ICF.

• Pure tone audiometry:

• Air-conduction hearing threshold at all frequencies ≤15dB.

• No air-bone-gap.

• Normal classical tympanometry: Jerger A (see fig. 1)

• CHL subjects

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.

• At least 18 years of age at the time of signing the ICF.

• Pure tone audiometry:

• Bone-conduction threshold at all frequencies ≤20dB.

• Two exceptions:

⁃ Age-related hearing loss: bone-conduction threshold ≤40dB in the higher frequencies (\> 2kHz).

• Carhart notch: bone-conduction threshold \>20dB around 2kHz. air-bone-gap ≥10dB at ≥ 1 frequency.

• CI recipients

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.

• At least 18 years of age at the time of signing the ICF.

• Ear is planned for CI surgery by treating ENT surgeon.

• Normal classical tympanometry: Jerger A.

Locations
Other Locations
Belgium
UZ Leuven
RECRUITING
Leuven
Time Frame
Start Date: 2025-07-04
Estimated Completion Date: 2027-11
Participants
Target number of participants: 45
Treatments
Experimental: conductive hearing loss
patients with isolated conductive hearing loss
Experimental: normal hearing
persons with normal hearing
Experimental: cochlear implant recipients
patients who undergo cochlear implantation
Related Therapeutic Areas
Sponsors
Leads: Universitaire Ziekenhuizen KU Leuven

This content was sourced from clinicaltrials.gov

Similar Clinical Trials